Accessibility Menu

D. Western Therapeutics Institute(FRA) 6DW

Market Cap€24.52MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPON/A
5 YearN/A
1 YearN/A
1 MonthN/A
€0.43
-1.39%
-0.01Today

D. Western Therapeutics Institute Financials at a Glance

Market Cap

€24.52MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€1.40

Net Income (TTM)

-€3.55

EPS (TTM)

-€0.07

P/E Ratio

-6.36

Dividend

€0.00

Beta (Volatility)

0.12 (Low)

Price

€0.43

Volume

0

Open

€0.43

Previous Close

€0.43

Daily Range

€0.43 - €0.43

52-Week Range

€0.32 - €0.86

Estimated Earnings Date

N/A

6DW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About D. Western Therapeutics Institute

D. Western Therapeutics Institute, Inc. engages in the research and development of pharmaceutical drugs. Its products include ophthalmic solution and agents for anti-platelet and anti-glaucoma. Its research and development laboratory undertakes drug design, screening of compounds, and selection of prospect compounds at early stage of drug research and development process. The company was founded by Hiroyoshi Hidaka on February 26, 1999 and is headquartered in Nagoya, Japan.

Industry

Biotechnology

Sector

Health Care

Employees

19

Website

www.dwti.co.jp

6DW Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-55.47%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-15.72%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€24.52MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

57.55M

Volume

0

Avg. Volume

72.576

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

D. Western Therapeutics Institute Performance Analysis

D. Western Therapeutics Institute annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 3,241,6471.6%
20232023-12-31EUR 2,817,835-13.1%
20242024-12-31EUR 2,877,7582.1%
20252025-12-31EUR 2,295,855-20.2%
D. Western Therapeutics Institute annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -0.10168.3%
20232023-12-31EUR -0.1760.3%
20242024-12-31EUR -0.2233.3%
20252025-12-31EUR -0.08-65.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€0.10

+0.2%

Gross Profit

€0.09

+0.3%

Gross Margin

89.74%

+1.2%

Market Cap

€24.52MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€1.07

N/A

Employees

19

N/A

Net Income

-€0.82

+0.8%

EBITDA

-€0.78

+0.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€11.65

+26.2%

Total Debt

€3.14

+1.0%

Accounts Receivable

€0.52

+1.1%

Inventory

€0.69

+1.2%

Long Term Debt

€2.31

+0.8%

Short Term Debt

€0.83

+7.4%

Return on Assets

-35.58%

+0.6%

Return on Invested Capital

-36.35%

+1.2%

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
WETOWetour Robotics
$5.48-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$71.92+0.00%
IBITiShares Bitcoin Trust
$44.67+0.02%
INTCIntel
$89.51+0.00%

Questions About 6DW

What is the current price of D. Western Therapeutics Institute?

D. Western Therapeutics Institute is trading at €0.43 per share.

What is the 52-week range for D. Western Therapeutics Institute?

Over the past 52 weeks, D. Western Therapeutics Institute has traded between €0.32 and €0.86.

How much debt does D. Western Therapeutics Institute have?

As of the most recent reporting period, D. Western Therapeutics Institute reported total debt of €3.14M.

How much cash does D. Western Therapeutics Institute have on hand?

D. Western Therapeutics Institute reported €8.51M in cash and cash equivalents in its most recent financial results.

What is D. Western Therapeutics Institute’s dividend yield?

D. Western Therapeutics Institute does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services